Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 530-535

  Ismael, Olfat ^a   Shimada, Akira ^a   Hama, Asahito ^a   Sakaguchi, Hiroshi ^a   Doisaki, Sayoko ^a   Muramatsu, Hideki ^a   Yoshida, Nao ^b   Ito, Masafumi ^b   Takahashi, Yoshiyuki ^a   Akita, Naohiro ^c   Sunami, Shosuke ^c   Ohtsuka, Yoshitoshi ^d   Asada, Youji ^e   Fujisaki, Hiroyuki ^f   Kojima, Seiji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c NARITA RED CROSS HOSPITAL   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e Department of Pediatrics   (Japan)

^f OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

ASXL1; Essential thrombocythemia; JAK2; Mutation; Polycythemia vera

Indexed keywords

ADDITIONAL SEX COMB LIKE 1 PROTEIN; CASITAS B LINEAGE LYMPHOMA PROTEIN; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; JANUS KINASE 2; TEN ELEVEN TRANSLOCATION 2 PROTEIN; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ALLELE; ARTICLE; BONE MARROW EXAMINATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CODON; EXON; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HUMAN; JAPANESE; MALE; MEGAKARYOCYTE; MISSENSE MUTATION; PEDIATRICS; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTHEMIA;

ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; JANUS KINASE 2; MALE; MUTATION; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84863880827     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23409     Document Type: Article

References (33)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood 1951; 6: 372-375.
2. Patnaik MM, Tefferi A. The complete evaluation of erythrocytosis: Congenital and acquired. Leukemia 2009; 23: 834-844.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
4. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
5. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
6. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
7. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-468.
8. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008; 111: 1686-1689.
9. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011; 29: 573-582.
10. Levine RL, Pardanani A, Tefferi A, et al. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673-683.
11. Tefferi A, Lim KH, Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 361: 1117; author reply 1117-1118.
12. Schaub FX, Looser R. Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003-2007.
13. Carbuccia N, Murati A, Trouplin V, et al. Mutations of ASXL1 gene in myeloproliferative neoplasms. Leukemia 2009; 23: 2183-2186.
14. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood 2009; 113: 6182-6192.
15. Tefferi A, Lasho TL, Abdel-Wahab O, et al. IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis. Leukemia 2010; 24: 1302-1309.
16. Teofili L, Giona F, Martini M, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007; 25: 1048-1053.
17. Teofili L, Foa R, Giona F, et al. Childhood polycythemia vera and essential thrombocythemia: Does their pathogenesis overlap with that of adult patients? Haematologica 2008; 93: 169-172.
18. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos. Cancer 2009; 115: 3842-3847.
19. Kim HJ, Jang JH, Yoo EH, et al. JAK2 V617F and MPL W515L/K mutations in Korean patients with essential thrombocythemia. Korean J Lab Med 2010; 30: 474-476.
20. Gelsi-Boyer V, Trouplin V, Adelaide J, et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788-800.
21. El-Moneim AA, Kratz CP, Boll S, et al. Essential versus reactive thrombocythemia in children: Retrospective analyses of 12 cases. Pediatr Blood Cancer 2007; 49: 52-55.
22. Thiele J. Philadelphia chromosome-negative chronic myeloproliferative disease. Am J Clin Pathol 2009; 132: 261-280.
23. Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006; 108: 3600-3602.
24. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 2005; 366: 1945-1953.
25. Cario H, Schwarz K, Herter JM, et al. Clinical and molecular characterisation of a prospectively collected cohort of children and adolescents with polycythemia vera. Br J Haematol 2008; 142: 622-626.
26. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010; 24: 1128-1138.
27. Teofili L, Larocca LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol 2011; 152: 701-712.
28. Rives S, Pahl HL, Florensa L, et al. Molecular genetic analyses in familial and sporadic congenital primary erythrocytosis. Haematologica 2007; 92: 674-677.
29. Semenza GL. Involvement of oxygen-sensing pathways in physiologic and pathologic erythropoiesis. Blood 2009; 114: 2015-2019.
30. Randi ML, Murgia A, Putti MC, et al. Low frequency of VHL gene mutations in young individuals with polycythemia and high serum erythropoietin. Haematologica 2005; 90: 689-691.
31. Percy MJ, Furlow PW, Beer PA, et al. A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. Blood 2007; 110: 2193-2196.
32. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N Engl J Med 2008; 358: 162-168.
33. Abdel-Wahab O, Manshouri T, Patel J, et al. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.